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Introduction
“Treat-all” programmes are being implemented in several 
African settings, as a HIV prevention and treatment 
strategy. In line with recent World Health Organization 
(WHO) guidelines, regular HIV testing is encouraged 
and antiretroviral therapy (ART) is offered immediately 
for those who are diagnosed HIV-positive, irrespective of 
immunological status and symptoms of disease (WHO, 
2015). Global narratives on the benefits of Treat-all 
implementation anticipate that earlier and increased access 
to ART will facilitate the “normalisation” of HIV, where it is 
considered a manageable chronic condition, and where 
stigma can be reduced through management of HIV related 
symptoms enabling HIV status concealment (Abadía-
Barrero & Castro, 2006; Roura, Urassa, et al., 2009; Roura, 
Wringe, et al., 2009b). Castro and Farmer (2005, p. 57) 
describe this transformation of HIV from a fatal disease to 
a chronic, manageable one as having “decreased stigma 
dramatically in Haiti”.
Stigmatisation can be defined as a social process 
occurring in the context of power, where an individual’s 
difference, condition or attribute is considered unfavourable 
and linked to negative stereotypes (Link & Phelan, 2001, 
2006). While the manifestations of stigma are socially 
constructed and context specific, possessing such an 
attribute generally results in loss of status, devaluation 
and discrimination, and leads to unequal outcomes for the 
stigmatised individual (Gilbert & Walker, 2010; Goffman, 
1963; Link & Phelan, 2001; Parker & Aggleton, 2003; 
Steward et al., 2008). In his seminal work on stigma, Goffman 
(1963) outlined the distinction between “discredited” and 
“discreditable” identities. Those who are discredited possess 
an evident or visible attribute, requiring them to devise 
coping mechanisms to manage the resulting prejudice and 
discrimination, which can also be referred to as “enacted 
stigma”. Conversely, conditions which can be hidden from 
the public eye create discreditable identities, where the main 
focus is managing and concealing information to “pass” as 
“normal”, to avoid becoming discredited and experiencing 
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the expected resultant stigma, which can also be referred 
to as “anticipated stigma” (Goffman, 1963; Scambler, 2009; 
Steward et al., 2008). 
A growing body of work has explored the relationship 
between stigma and taking ART. Mattes (2014) refers to 
ART as a “technology of invisibilisation”, as it provides an 
opportunity to maintain status secrecy and to thereby avoid 
stigma, a concept which is also reflected in the work of 
other scholars (Beckmann, 2013; Moyer, 2012). However, 
while ART may enable the avoidance of enacted stigma 
(Beckmann & Bujra, 2010) and prevent people living with 
HIV (PLHIV) from being discredited, anticipated stigma can 
persistently prevail in people’s lived experiences with HIV 
(Alonzo & Reynolds, 1995). PLHIV remain discreditable, 
partly due to the potential for symptom development and 
status exposure, but also because ART does not directly 
address the structural drivers of stigmatisation (Russell et 
al., 2016), such as poverty, gender inequality and racism 
(Link & Phelan, 2001). Stigma reflects the workings and 
forms of social inequality, and to properly understand it 
we must consider how some people come to be socially 
excluded, and the forces that create and reinforce such 
exclusion (Parker & Aggleton, 2003). Additionally, ART 
does not address the fundamental causes of stigma, 
including the deeply held views of powerful groups that lead 
to stereotyping and labelling (Link & Phelan, 2001), and 
Squire (2010, p. 409) argues that the association of HIV with 
“transgressive sexuality, particularly for women, will always 
render it socially pathological”. 
HIV related stigma presents a major barrier to the 
prevention and treatment of HIV (Mbonye et al., 2013; 
Stangl, Lloyd, Brady, Holland, & Baral, 2013; Steward et 
al., 2008). In African settings, and particularly in Southern 
and Eastern Africa, stigma has been found to discourage 
care-seeking (Maeri et al., 2016), and undermine uptake 
of HIV testing, ART initiation and adherence (Bond, 
2010; Genberg et al., 2009; Mbonu, van den Borne, & De 
Vries, 2009; Mbonye et al., 2013; McGrath et al., 2014; 
Orne-Gliemann et al., 2016; Sengupta, Banks, Jonas, Miles, 
& Smith, 2011). Stigma can undermine adherence and 
engagement directly, where attempts at status concealment 
such as hiding treatment or selecting clinics far from home 
contribute towards treatment interruptions (Dlamini et al., 
2009; Gilbert & Walker, 2010; Katz et al., 2013). There 
are also indirect influences, whereby non-disclosure of 
HIV status results in lack of social support and treatment 
reminders (Katz et al., 2013). While this body of research 
explores stigma and HIV service engagement for 
symptomatic PLHIV, where the discrediting attributes are 
made visible by the disease itself, it is not yet known how 
this may be experienced by clinically asymptomatic PLHIV in 
the context of Treat-all, where the discrediting risk is made 
manifest only through accessing treatment. 
Supporting PLHIV to engage with treatment and care 
is important for individuals’ health outcomes, as delayed 
treatment and suboptimal adherence have deleterious 
effects on morbidity and mortality (INSIGHT START Study 
Group, 2015; Song et al., 2018; TEMPRANO ANRS 12136 
Study Group, 2015). Additionally, suboptimal adherence 
can contribute to drug resistance, which can be transmitted, 
with resultant population level and individual level risks, and 
which has been highlighted as a critical threat to eliminating 
AIDS by 2030 (WHO, 2017a, b). Without detailed exploration 
of whether and how stigma is manifested and experienced in 
this context, it is unknown how it may undermine Treat-all 
efforts. To ensure stigma is addressed, it must first be 
understood, ideally by examining the perspective of those 
affected. In this context, we aim to examine how stigma 
shapes PLHIV experiences with HIV, and engaging with HIV 
treatment and care services under Treat-all in Shiselweni, 
Eswatini (formerly Swaziland). 
Methods 
This study is situated within the context of a broader 
research project that used a longitudinal qualitative design 
to examine the lived experiences of clinically asymptomatic 
PLHIV, their engagement with HIV treatment and care, and 
how these changed over time in the context of Treat-all in 
Shiselweni, Eswatini. 
The study of lived experiences refers to understanding 
individuals’ experiences, choices, and options, and how 
individuals interpret and make sense of their experiences 
(Given, 2008; Smith, 2004). This approach aims to understand 
and describe individuals’ experiences of their everyday world 
as they see it (Liamputtong, 2013), and to remain as faithful 
as possible to the phenomenon and the context in which it 
appears in the world (Giorgi & Giorgi, 2008).
Study context
Eswatini has the highest reported HIV prevalence worldwide, 
estimated at 35% among women and 19% among men aged 
15–49 years (UNAIDS, 2016). HIV prevalence peaks at 
54% among women aged 35 to 39 years and 49% among 
men aged 45 to 49 years (Swaziland Ministry of Health, 
2017). Most transmission occurs through heterosexual sex 
(Swaziland Ministry of Health, 2012). 
Eswatini is the last remaining absolute monarchy in Africa. 
Classified as a lower middle-income country, it is a small, 
largely mountainous country with a population of 1.2 million 
people. Sixty per cent of the population lives in poverty, of 
which 38% live in extreme poverty, and income inequality 
is high (World Bank, 2018). Limited economic opportunity 
and high unemployment have resulted in widespread 
dependence on labour migration, with most migrant 
labourers travelling to neighbouring South Africa for work 
(Hickel, 2012). Most people identify as Christian (90%), and 
the main land use is pastoral, and timber forest (CIA, 2018). 
In the predominantly rural southern region of Shiselweni 
subsistence farming is widely practised, and the region 
has been particularly affected by drought in recent years, 
which has caused food insecurity (Root, Van Wyngaard, & 
Whiteside, 2017). 
In October 2014, a Ministry of Health/Médecins Sans 
Frontières (MoH/MSF) Treat-all implementation pilot began 
in the predominantly rural Nhlangano health cluster in 
the Shiselweni region. This aimed to contribute towards 
reduced HIV incidence and improved clinical outcomes 
for PLHIV. The population in Nhlangano largely access 
HIV treatment and care at primary health clinics. The area 
has eight primary clinics and one secondary health facility; 
some people have to travel long distances, often on foot, to 
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reach the nearest clinic. Treat-all was rolled out nationally in 
October 2016.
Participant recruitment
Participants were recruited purposively to include PLHIV 
enrolled in the Treat-all pilot programme who were 
considered clinically asymptomatic and who would have 
been otherwise ineligible for treatment at the time of ART 
offer (CD4 count ≥500, WHO disease stage 1), and to 
include a range of treatment-taking experiences (see 
Table 1). The project patient cohort was stratified for gender 
and age, to include young people (aged 16 to 25 years) and 
adults (aged 26 to 49 years). Healthcare workers (HCWs) 
from the facilities implementing Treat-all (one secondary 
and eight primary care facilities, not HIV-specific) were 
purposively recruited to include a range of positions involved 
in the delivery of HIV testing, treatment and care, and both 
MoH and MSF personnel. Fieldwork was conducted from 
February 2015 to November 2017. Identified PLHIV were 
contacted in June 2016 and invited to participate in between 
2 and 4 interviews over a 12-month period, while healthcare 
workers (HCW) were invited to participate in 1 interview 
during March and April 2017. 
Attempts were made to contact 107 PLHIV identified 
for potential recruitment, 55% of whom (n = 59) were 
non-contactable. Of those who were contactable (n = 48), 
30 agreed and participated, 9 agreed and did not attend the 
agreed appointment (reason for non-participation unknown), 
2 refused due to work commitments limiting their time in 
the area, 5 were out of the region and 2 were unwell and 
therefore unable to meet. All HCW who were approached 
and invited to participate agreed to an interview.
Data generation and analysis
In-depth interviews were conducted to explore a range 
of topics relating to PLHIV’s lives, their experiences of 
living with HIV, and with treatment and care (see Table 2 
for a summary of topics). Interviews were based on topic 
guides but were primarily participant-led, for example, 
HIV status was not asked about unless participants 
themselves disclosed their diagnosis (which all participants 
did). Multiple waves of data generation were conducted 
to capture changes over time, and also to benefit from 
developing rapport between participants and the researcher, 
which produced richer quality data. Data generation and 
analysis followed an iterative process, with topic guides 
for subsequent interviews being based on initial findings, 
to further test and explore particular areas emerging as 
potentially important. Interviews were conducted in siSwati 
by same-gendered interviewers, mostly held at participants’ 
homes, or another location of their preference if they felt 
more comfortable (e.g., fixed testing site in town). The 
interviews were audio-recorded following participant consent 
and were then translated and transcribed. Interviews with 
HCW were conducted at clinics, mostly in English, and 
explored topics relating to their experiences implementing 
Treat-all including offering ART to those considered clinically 
asymptomatic, supporting patients, and related challenges 
faced by patients and HCW. 
Interview transcripts were analysed thematically using 
NVivo 11, drawing on principles of grounded theory to 
generate findings inductively from participant accounts 
and to actively investigate discrepancies from the 
majority of themes (Bradley, Curry, & Devers, 2007; 
Glaser, 1999; Glaser & Strauss, 1967). Initial coding and 
themes were discussed collaboratively, with a coding 
framework developing as analysis progressed. Repeated 
Table 1: Participant characteristics
Participant information* n
All PLHIV 30
Treatment-taking category
On ART 18
Lost from treatment 12
Enrolment period
Early (October 2014–March 2015) 13
Mid (April 2015–September 2015) 12
Late (October 2015–March 2016) 5
Gender and age
Women
Young women (17–25 years; average 21)
Adults (26–46 years; average 33)
18
9
9
Men
Young men (16–25 years)
Adults (26–49; average 37 years)
12
0 (none eligible in 
patient cohort**)
12
All HCW 20
Position
Nurse supervisor 5
Nurse 8
Adherence counsellor 5
Doctor 1
Employer
MoH 12
MSF 8
*Participant information relates to that recorded on the project 
patient database at time of recruitment, or for HCW the positions 
they identified with during interviews
**No young men were eligible due to the epidemiology of HIV in 
Swaziland meaning fewer young men are infected, and additionally 
men can access care later.
Table 2: Longitudinal interview time frame
Interview Date range Participants (n) Meetings (n)
1. Life history, family and relationships, hopes and aspirations, key life events 22/08/16–31/10/16 30* 33
2. HIV testing, diagnosis, treatment offer and treatment initiation decision-making 17/11/16–07/02/17 29 31
3. Living with HIV, ongoing treatment-taking and engagement with HIV services 25/03/17–08/09/17 26 27
*Certain interviews were conducted over more than one meeting, for example, due to length of discussion and available time; one participant 
was lost to follow-up after the first interview, attempts were made to contact her but she was not available to arrange another meeting; three 
participants completed two interviews and one completed four interviews. 
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interviews with PLHIV were initially analysed per round to 
examine themes across participants’ accounts, and then 
longitudinally to explore how patients’ narratives changed 
over time. Ethical approval was received from the Swaziland 
Scientific and Ethics Committee, London School of Hygiene 
and Tropical Medicine and from MSF Ethics Review Board. 
Pseudonyms are used in this paper for PLHIV participants, 
and HCW participants are referred to as HCW, to ensure 
confidentiality.
Results
In total, 106 interviews were conducted between August 2016 
and September 2017, including 86 interviews with 30 PLHIV 
(Tables 1 and 2) and 20 interviews with HCW (Table 1). 
Stigma emerged inductively from participants’ accounts of 
living with HIV and engaging with HIV treatment and care 
services. Stigma was then explored further in later interviews 
to gain greater depth of understanding into the ways in which 
it affected individuals’ sense of identity, their interpretation 
of their diagnosis, and their engagement with treatment and 
care. HCW interviews also highlighted the ways in which 
stigma frames and influences PLHIV’s engagement with 
treatment and care in the context of Treat-all. Figure 1 shows 
a summarised depiction of these findings.
HIV status concealment to avoid anticipated stigma
Anticipated stigma was pervasive within PLHIV participant 
narratives, and almost all described feeling that they must 
conceal their HIV status to avoid stigma through being 
singled out and treated differently by those around them. 
The importance of status secrecy also appeared reinforced 
through health messaging at the point of treatment initiation 
and subsequent clinic visits, with some health workers 
encouraging their patients not to widely disclose their 
diagnosis.
When you are HIV-positive you must keep it a secret 
(Hlobsile, woman (F), second interview).
They [HCW] said going around telling people isn’t a 
good thing… they explained this to us at the clinic 
that we should tell someone who will not go around 
talking about you (Cebsile, F, third interview).
Many PLHIV feared the potential negative consequences 
of having their status discovered. The fears should they be 
identified as taking treatment included not wanting to be 
gossiped about, made a mockery of, or to experience social 
judgement which could result in loss of reputation, social 
stature and standing, which in turn could impede future 
relationship and marriage prospects. 
It lowers your value when people point at you for 
taking the treatment. People will not respect me the 
way they do now, and they will not treat me the way 
they treat me now (Nokuthula, F, second interview).
Engagement with Treat-all HIV care, wan�ng ART when 
asymptoma�c, mo�va�on for treatment-taking
Hiding status
Exposing status
Preven�ng 
visible 
symptoms
Looking 
healthy
Not 
bedriddenStrength Produc�vity
ART changing 
appearance e.g. 
weight, hair
Fears about 
side eﬀect 
visibility
Being seen 
with ART
Being seen 
at clinic
Disengagement from Treat-all HIV care, intermi�ent 
treatment-taking, treatment interrup�ons
Figure 1: How stigma and status concealment versus exposure influence PLHIV’s engagement with HIV treatment and care under Treat-all
African Journal of AIDS Research 2019: 1–11 5
Commonly held notions of what comprises a good, 
upstanding citizen, in line with Christian values and moral 
standards, appeared contradictory to, and threatened 
by, views about who gets HIV. Most participant accounts 
included references to the ways in which HIV continues to be 
abnormal and morally judged, particularly linked to the sexual 
nature of transmission, and with negative connotations 
regarding the sexuality and behaviour of PLHIV.
I wish that people could take AIDS as a common 
cold, because it can get anyone, not that they take 
you as an animal, or that you were living a life that is 
not good, you see (Thandi, F, first interview).
Religion comes in, and if you do go to church we 
don’t expect you to be having sex when you are not 
married, but you are actually having sex, so you 
can’t talk about it (laughs) and then at the same time 
this is a very small community, so everybody knows 
everybody. I know you go to church, and if I then 
know that you are sleeping with this one, it means 
you are not actually an outstanding Christian if I may 
say (HCW).
The impact of such anticipated stigma could be strong and 
harmful. Some participants described considering suicide, 
linked to the humiliation, shame and devaluation that could 
come from having their status known: 
I even wished to kill myself because I had lost so 
much weight and people in the community were 
making a mockery of me (Sanele, young woman 
(YF), second interview).
ART offering the potential to maintain good health and 
a hidden HIV status
Initiating ART while still largely asymptomatic and with good 
general health, offered both risks and opportunity. ART 
was a means to avoid signs or symptoms of ill health from 
developing, which could expose one’s HIV status. Avoiding 
HIV visibility appeared more important than maintaining 
good health itself, with the fear of being identified being 
more pervasive than the fear of experiencing sickness. 
I should just start taking the treatment while I am 
still walking on my own, while I am still healthy, and I 
shouldn’t go down but instead I should improve from 
where I am now… so that I wouldn’t lie down and 
be identifiable and then lose weight and many other 
things (Vusi, man (M), second interview).
Maintaining good health, including strength and energy, 
enabled the maintenance of a sense of normality, being able 
to work and function as a member of society, contradicting 
stigmatising processes of “othering” and countering feelings 
of no longer being a human. This appeared particularly 
important for men, who described wanting to work and 
provide for their family, thereby upholding notions of 
masculinity and productivity.
When I’m healthy, my family will have something to 
eat and my children will be able to go to school and 
they wouldn’t have problems… if I might get sick 
then I think my children will struggle because what 
they get from me it’s something they cannot get from 
anyone [else] (Mandla, M, second interview).
Many participants described having seen the effects of 
delayed ART initiation, for example, with family members or 
neighbours becoming sick and bedridden, which reinforced 
their motivation to start treatment before succumbing to 
these symptoms: 
I saw from my sister, she started them late when she 
was very sick and I said I do not want to get to that 
stage, let me start them while I am walking because 
when you are sick people then start to gossip about 
you (Sanele, YF, third interview).
Though all participants were considered clinically 
asymptomatic, several described experiencing embodied 
signs of HIV, such as headaches, weakness, lethargy and 
weight loss, which served to warn them of the potential for 
imminent health deterioration and therefore HIV visibility 
without ART. Perceptions of health and ill-health appeared to 
differ experientially from biomedical definitions regarding the 
severity of HIV related disease (e.g., those included in WHO 
disease staging). For some, even receiving a HIV diagnosis 
pointed to a fragility in their health status, reinforcing their 
sense of needing to start ART. 
When you haven’t tested, you are going to tell 
yourself that you’re okay but once you have things 
like constant headache and things like that, you 
must know that those are the signs… We know the 
symptoms, like if your hair is like it has been licked 
by a calf… Forget it just go and start taking the 
treatment, there’s nothing you can do (Jabulane, M, 
second interview).
It hurt me… [after HIV diagnosis] you then begin 
to see yourself that you’re not someone who is 
healthy, you’re someone who is sick (Sifiso, M, third 
interview).
Health workers also felt that a key driver for PLHIV to 
initiate ART before becoming symptomatic was the ability of 
ART to hide their status, relating this to anticipated stigma. 
Usually it is that they don’t want to be sick, to be seen 
by everyone that this one is now sick… once you get 
sick, be in a wheelchair, they [community members] 
diagnose you as being HIV positive… there will be 
rumours all over. They still want their status to be 
confidential. They test and initiate but are not ready 
to disclose in public. It is self-discrimination (HCW).
[Treat-all] has helped us greatly because if a 
person is initiated today on ART nobody will see 
that the person is HIV positive because there 
are no hair changes and no nothing. By that the 
stigma… because once the symptoms… manifest, 
discrimination begins… (HCW).
In addition, certain HCW alluded to this message being 
reinforced in pre-ART sessions with PLHIV: 
They eventually want to take them because we tell 
them: why do you want people to see you that you 
are sick? Because you could take even when no one 
is noticing, and you will continue (HCW).
As well as wanting to initiate ART to ensure HIV status 
concealment, the perceived need for, and benefit of ART 
in enabling a hidden status was said to motivate ongoing, 
continued treatment-taking:
The thought of stopping treatment never crossed my 
mind because I am the one who will get exposed if I 
stop taking them… I respect them [ARVs] a lot they 
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have helped me, if it was not for them, I would also 
be visible that I am sick, so really I respect them a lot 
(Welile, F, third interview).
The risk of HIV status exposure undermining 
engagement with HIV treatment and care
While many PLHIV appeared motivated to take treatment 
early to protect a hidden status, engagement with HIV 
treatment and care services could itself be exposing and 
therefore discrediting. Almost all participants described fears 
of being seen at clinics, or having their treatment found:
When you are going to the hospital you are 
ashamed, even just walking around you are 
ashamed because you know that people know that 
you are positive, and then others will point you using 
their heads and have names for you, you find that 
they call you Khumalo [one who takes] (Sanale, YF, 
third interview).
Many PLHIV could go to great lengths to hide their 
treatment, and at times these efforts undermined their 
capacity to take it. For example, a dose may be missed 
when others were present to avoid being seen and 
therefore exposed: 
Sometimes you would find that when the time for 
taking the treatment comes he is also in the room, so 
it would happen that I wouldn’t take them (Nelisiwe, 
YF, third interview).
I am scared to say ‘yey people get out so that I can 
take my bag and drink my treatment’. I am scared, 
so I end up skipping, and this makes me stressed 
(Nontokeko, YF, third interview).
Participants also reported that they feared the risks of 
being seen at the clinic while queuing for ART refills. Some 
described strategies they adopted in order to minimise this 
risk, including befriending HCW to avoid the need to queue, 
or choosing a clinic further from their home community to 
avoid the risk of being seen by neighbours. However, these 
strategies were often fragile or less convenient, which 
inadvertently added to the burden and fragility of treatment-
taking. This could potentially undermine the sustainability 
of longer-term engagement with treatment and care. The 
strategy of selecting a clinic which was further away from 
home in order to avoid exposure was particularly described 
by young women and by men, who were less easily able to 
justify their presence at the clinic by citing an alternative and 
more socially acceptable reason than, for example, older 
women. 
I do not want to lie to you [interviewer surname], I 
have never queued and I feel like I am scared to. 
I feel like I am not ready to be seen by everyone 
that I am HIV positive. You see where you sit there, 
I have never sat there… I just come and go inside 
(Hlobsile, F, third interview).
I transferred from Nhlangano to Big Bend… aunt 
said I should transfer because people around here 
know me, so they might know me and see me and 
be gossiping about me… she said it is better that I 
go where they do not know me (Thobile, F, second 
interview).
Some PLHIV also described times when they turned back 
from the clinic without collecting their refill due to seeing 
someone they knew at the clinic and not wanting to be 
exposed:
They said because I am pregnant I have to go to 
the VCT and when I looked at it the Nhlangano 
VCT the way it is, I just left everything there and 
then… it exposes too much sisi… I was like I will be 
discovered by people I work with… so I was like no 
ways (Welile, F, second interview).
Someone might decide to leave the treatment 
because there’s a relative of mine in the clinic, or 
the cleaners or something, she knows me and she’s 
going to talk (HCW).
Although early initiation on to ART was understood to 
prevent symptom development, some saw ART itself as 
concomitantly potentially exposing, with fears that treatment 
side effects could cause physical deformities, changes in 
weight, hair and skin colour. This is indicative of the dilemma 
that the prospect of Treat-all posed for asymptomatic PLHIV, 
as ART could be the catalyst for their status to become 
noticeable, with treatment related side effects perceived as 
potentially revealing their HIV to others.
I do not want to lie, part of me was saying I should 
take them but another part was saying I shouldn’t 
take them… I am scared of them making a problem 
of me and I would be like a written book, look at 
her she doesn’t have a big belly anymore, she is 
finished with a flat ass, you are now written that 
you are taking treatment you see, I was scared of 
them, telling myself that they [ART] will expose me 
(Hlobsile, F, third interview).
I thought that the treatment would make me sick and 
I would be seen by all people because I would’ve 
changed so much than what I was before (Lindiwe, 
F, second interview).
I was actually afraid of gaining weight because it 
was now a common thing that once you gain weight, 
whether I have told this person or not, but once 
I gain weight they are going to say I have started 
taking the treatment… I was really afraid that people 
were now going to identify me easily (Mandla, M, 
third interview).
Maintaining a hidden HIV status whilst engaging with 
HIV treatment and care services thus appeared fragile. 
Participant accounts were interwoven with calculations of 
perceived benefits and risks of treatment-taking and status 
exposure, which were continually considered and navigated 
over time. If the risk of exposure was deemed too great, this 
could cause individuals to disengage from treatment and 
care services: 
It is not pleasing to be on a treatment for the rest of 
your life, and also that you can hide it today but for 
how long? Because there are people that you do not 
want to know about you taking treatment… you can 
hide it from them today and tomorrow, but they will 
end up finding out about it because the hospital is 
not mine alone (Nontokeko, YF, third interview).
When you are talked about, and when you are 
scared, you may end up saying let me just stop 
taking this thing. This is what can make people stop 
taking treatment (Sanele, YF, third interview).
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I was not collecting them anymore… what was in my 
mind was that I was scared to tell my boyfriend that 
it is my time to collect my treatment, I was scared to 
do that… (Ncobile, YF, fourth interview).
HIV status acceptance countering anticipated stigma 
The extent to which PLHIV’s engagement with HIV 
treatment and care services was framed by avoiding 
exposure and anticipated stigma appeared to be influenced 
by their own interpretation of their diagnosis. Only four 
participants did not mention trying to hide their status, 
and for these participants, their own acceptance of being 
HIV-positive and wanting to live seemed to support their 
overcoming fear of others’ judgement, thereby also 
supporting their engagement with care. 
Whatever situation you go through, what will help 
is that you accept yourself first, so that you get 
accepted by other people. When you start having 
self-stigma [utinyandza wena], then at that time 
you feel like I am not the same as other people… I 
accepted myself a long time ago, in the beginning. 
That is what made me live, that I just accepted 
myself. I never found myself as different, even if you 
could come and say “I am not positive”, that does 
not hurt me… I find that we are the same. You can 
be negative and I know that I am positive, it does not 
make any difference to me… when they said I am 
positive so what, there is treatment, they say it helps, 
I will continue to live (Philile, F, second interview).
Such acceptance of status could be challenging in the 
absence of any symptoms or signs of ill health. Some did 
not perceive the need for ART in the absence of symptoms, 
questioning their diagnosis or the likelihood of experiencing 
future health deterioration, and wanting to wait before 
starting ART: 
I thought for myself that I do not have to take them 
because I feel okay… maybe when I get sick and I 
can see that I have to take the treatment (Gcinile, F, 
second interview).
Some… they say they are not ready, they are still 
fine… they tell you that there is no need, they will 
start treatment when they are sick, not now (HCW).
Treat-all could expedite the time from HIV diagnosis to 
treatment initiation, but for many it appeared important 
to have time to process and come to terms with a HIV 
diagnosis, to feel ready for treatment, and for people to know.
I think it is still processing for me to accept it… I 
think that after some time I will end up not caring if 
people know, it is just for now… (Nokuthula, F, third 
interview).
I think that as time goes on I will be alright, I will 
then accept it... but I do not know yhiii… what can 
be done… it is still new, just like losing a mother, you 
keep thinking about her but as the years go by you 
then forget that she died and I cried at the funeral. 
So I think I will also be alright (Nontokeko, F, third 
interview).
Discussion
In the context of Treat-all, in a setting with a high prevalence 
generalised HIV epidemic, stigma was pervasive and 
influential in participants’ accounts of living with HIV, and 
appeared to strongly frame PLHIV’s engagement with 
treatment and care services. On the one hand, treatment 
appeared as a pulling force, offering the potential to 
preserve good health, so that any symptoms which may 
expose HIV could be avoided. This motivated many PLHIV 
to want to start treatment early, when considered clinically 
asymptomatic. However, being on treatment and engaged 
with HIV care services could also be exposing, and many 
had fears around being seen collecting refills or having 
their treatment discovered, which could undermine their 
engagement. Avoiding anticipated stigma appeared so 
important that some participants thought of suicide if they 
were to be discovered living with the virus, and to experience 
the expected humiliation and devaluation that could result. 
While there is a wealth of research on HIV related stigma 
and its interplay with use of HIV services, to the best of 
our knowledge this is the first study to unpack in detail the 
ways in which stigma influences asymptomatic PLHIV’s 
engagement with Treat-all. 
Status concealment appeared as an information 
management strategy, through which PLHIV maintain 
a discreditable identity and avoid becoming discredited 
(Goffman, 1963). The need to conceal was reinforced by 
health messaging at clinics, potentially implying that there 
is something inherently wrong with being HIV-positive 
(Bernays, Paparini, Seeley, & Rhodes, 2017). Our finding 
that almost all participants felt they must conceal their HIV 
status due to anticipated stigma has been shown by others 
(Alonzo & Reynolds, 1995; Dlamini et al., 2009; Katz et al., 
2013). While all PLHIV participants were considered clinically 
asymptomatic, several described embodied signs of HIV, 
which served to warn them of the potential for imminent health 
deterioration and discrediting without ART, and supported 
their motivations for initiating ART. This also highlights the 
dissonance between biomedically ascribed markers of HIV 
(e.g., CD4 count and WHO disease stage) and PLHIV’s 
experiential conceptions of their health and illness.
The ability of ART to alleviate physical manifestations 
of HIV have led to it being referred to as a technology of 
“invisibilisation” (Beckmann, 2013; Mattes, 2014), enabling 
social and economic engagement, and therefore providing 
PLHIV with a sense of value (Bernays, Rhodes, & Terzic, 
2010; Campbell et al., 2011; Mattes, 2014). In our study, this 
manifested in the ability of ART to prevent the development 
of physical symptoms, rather than alleviate them once 
present. Other studies describe the transformative and 
restorative effects of ART when taken by PLHIV who are 
very unwell, which can then motivate adherence (Bernays, 
Seeley, Rhodes, & Mupambireyi, 2015; Russell & Seeley, 
2010). Our findings that participants were motivated to start 
and continue taking treatment in the absence of symptoms 
show how the relationship with ART, and its capacity to 
conceal HIV, are changing under Treat-all. 
While ART can present a technology of “invisibilisation”, 
some authors have suggested that wider treatment 
availability can generate new forms of stigma (Roura, Urassa, 
Horter, Bernays, Thabede, Dlamini, Kerschberger, Pasipamire, Rusch & Wringe8
et al., 2009). Although being visibly healthy can conceal an 
HIV-positive status, clinic visits and daily medication use can 
create privacy concerns and risks of exposure (McGrath et 
al., 2014; Moyer & Hardon, 2014). Many PLHIV in our study 
had concerns about the risk of exposure from engaging with 
treatment and care, which could cause intermittent treatment-
taking, interruptions and disengagement from treatment 
and care. Hiding treatment can lead to non-adherence 
and treatment interruptions (Dlamini et al., 2009; Katz 
et al., 2013; Maeri et al., 2016), and in our study several 
participants described times when they felt unable to take 
their medication if others were present.
The extensive efforts PLHIV in our study described 
in order to maintain privacy, such as choosing to attend 
clinics long distances from their home communities, have 
been found by others (Bond, 2010; Gilbert & Walker, 
2010; Maeri et al., 2016), and as affecting individuals’ 
ability to remain adherent to ART (McGrath et al., 2014), 
for example, through increasing the burden of treatment 
and undermining longer-term sustainability. However, our 
findings illustrate the dilemma that individuals experience 
because some perceive that not engaging in treatment, in 
the hope of continuing to remain asymptomatic, may allow 
a continued invisibility of their HIV status for longer. In the 
past, the risk of exposure from engaging with treatment 
could potentially be balanced with the risk of exposure from 
visible signs of HIV before starting ART. In the Treat-all 
context, where PLHIV were visibly asymptomatic before 
initiation, these risks of exposure may actually seem 
greater with treatment-taking than without it, as the risk 
of developing symptoms in the future are perhaps more 
abstract and less current than those experienced presently. 
There is a risk that the effect of this is to delay treatment-
seeking. Likewise, while some studies have found that 
PLHIV may have concerns about visibility linked to ART 
side effects (Mattes, 2014; Mbonye et al., 2013, 2016; 
Zhou, 2016), in our study these concerns could influence 
the cost-benefit weight of ART unfavourably, as treatment 
may be felt to cause changes to appearance which were 
more exposing than PLHIV’s health before starting. If these 
perceived risks are not addressed within programmes, this 
could undermine the success of Treat-all implementation.
Self-acceptance of HIV status appeared to counter stigma, 
helping individuals to overcome the fear of others’ judgement 
and not to internalise stigmatising attitudes and shame. The 
influence of HIV status acceptance on PLHIV’s engagement 
with treatment and care in Swaziland is reported elsewhere 
(Horter et al., 2017). Others have found that status acceptance 
has supported the choice to live, to overcome fear of stigma 
and to support adherence (Gilbert & Walker, 2010; Katz et 
al., 2013; Nixon et al., 2018). We found that some PLHIV 
felt it could take time to process and come to terms with an 
HIV-positive result, which may be expedited under Treat-all 
as the time between diagnosis and treatment initiation can 
be reduced. This highlights the importance of considering 
individual patient readiness and acceptance of HIV status 
within Treat-all and same-day treatment approaches. 
Many authors have described the ways in which HIV is 
associated with immorality and deviant sexual behaviour 
(Mattes, 2014; Mbonu et al., 2009; Mbonye et al., 2013; 
Moyer & Hardon, 2014; Roura, Wringe, et al., 2009; Roura, 
Urassa, et al., 2009), with PLHIV therefore being blamed 
for their infection, and HIV deemed as a punishment for 
those who have challenged sexual and gendered social 
norms (Campbell et al., 2011). HIV stigma can thus be 
seen as central to the establishment and maintenance of 
social order (Foucault, 1977, 1978; Parker & Aggleton, 
2003) and control of sexual behaviour (Mbonu et al., 2009), 
which can be reinforced and upheld by religion, with PLHIV 
being considered sinful or evil (Alonzo & Reynolds, 1995; 
Duffy, 2005). This is of particular relevance in the study 
setting, where the population is predominantly Christian, 
and participation in religious and church activities are an 
important part of culture and personhood.
Several studies have shown that individuals judged in 
association with HIV and immorality can experience great 
shame, indignity and humiliation (Campbell et al., 2011; 
Gilbert & Walker, 2010; Mbonu et al., 2009; Mbonye et al., 
2013). Respectability is an important aspect in the social 
construction of value and personhood (Campbell et al., 
2011), lending understanding as to why several participants 
in our study who anticipated stigma also contemplated 
suicide. Our finding mirrors that of Moshabela et al. (2016, 
p. 27) in South Africa, where it was felt “better to die with 
dignity, than live with shame” from being known to be 
HIV-positive. Additionally, a study conducted in the same 
region of Swaziland as our study (Shiselweni) reported 
suicidal ideation following HIV diagnosis and as a result of 
anticipated stigma (Root et al., 2017). However, there is 
also a powerful strand of “responsibilisation” which could 
be emphasised, where initiating ART early allows for 
continued productivity. This could be particularly effective 
for men, by appealing to the prevailing discourse of 
masculinity, which is imbued with the need to provide for 
their families (Siu, Seeley, & Wight, 2013). These findings 
highlight the importance of understanding and considering 
the social experiences of individuals as integral to the HIV 
response, and the need to acknowledge stigma and its 
influence on PLHIV’s lived experiences. 
The longitudinal approach that was adopted in our 
study supported rapport and relationship building between 
interviewer and participant. This helped with the discussion 
of sensitive topics such as stigma, and facilitated access 
to alternative layers of participants’ narratives, beyond 
those deemed to be socially acceptable. This approach 
also enabled a greater depth of understanding, and insight 
to the nuanced ways in which stigma accounts changed 
over time. These findings are situated within a specific time 
and place, relating to a fairly early stage in the Treat-all 
pilot, where it was uncommon for people who were 
relatively healthy to be accessing ART, and before national 
implementation. It will therefore be important to see how 
these findings continue to evolve as Treat-all becomes 
more commonplace. While likely to be of relevance to 
similar contexts, our findings reflect the voices of particular 
participants in a particular context, and therefore should be 
considered with this in mind.
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Conclusion 
With increased and earlier access to ART in a high 
prevalence, generalised HIV epidemic setting, stigma 
persists to frame PLHIV’s experiences with HIV, and to 
shape their engagement with HIV treatment and care. 
Taking treatment and engaging with care presents both 
benefits and risks for HIV status concealment, which must 
be continually negotiated and navigated. PLHIV may be 
motivated to initiate ART early to remain hidden by avoiding 
the development of discrediting stigma symbols, i.e. signs 
and symptoms of HIV. However, engaging with treatment 
and care itself presents risks of exposure at multiple points, 
and for some this risk was deemed too great, with decisions 
to abandon treatment and care being described. Where 
individuals are engaging with treatment and care as a 
means to hide their status, this is likely to be fragile, with the 
risk of non-adherence or disengagement from care. 
These findings point to the continued need for efforts 
to address the root causes of stigma and stigmatising 
processes where those with HIV are labelled with harmful 
judgements of difference, deviance and immorality. Regular 
measurement of community HIV stigma index could be 
beneficial, and programmes should ensure individual 
PLHIV are ready for treatment, have accepted their status 
and are not choosing to take treatment primarily to remain 
hidden, as this could undermine the sustainability of their 
engagement. Addressing HIV related stigma is crucial 
for the success of Treat-all, and should thus be a core 
component of HIV responses. 
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